MacroGenics discontinues vobra duo dosing in TAMARACK Phase 2 mCRPC study on IDMC safety recommendation

MACROGENICS INC

IDMC recommended stopping dosing for remaining participants; most had received 8-12 cycles.
Emerging adverse events from prolonged exposure cited; participants continue safety and survival follow-up.
Primary endpoint 6-month rPFS data to be presented at ESMO Congress September 2024.
Company will not hold Q2 2024 earnings call; financial results release expected August 6.
Investor conference call planned after ESMO presentation to discuss next steps for vobra duo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.